“…EPO increases the risk of thrombosis, and the dosage used in this study is higher than the doses commonly used in the clinic. Although a single bolus of high‐dose EPO increases the hematocrit only to a minor extent, if at all, EPO should be used with caution, especially in critically ill patients, who are already at an increased risk of vascular thrombosis 18,30 . Recently, new EPO‐like derivatives, such as desialylated EPO (asialo‐EPO) and carbamoylated EPO (CEPO), have been developed.…”